1	Immune response induced by the Recombinant Novel Coronavirus Vaccine (Adenovirus
2	Type 5 Vector) (Ad5-nCoV) in persons living with HIV (PLWH)
3	Immune response induced by the Recombinant Novel Coronavirus Vaccine in persons
4	living with HIV
5	P. Cahn ¹ , L. Barreto ⁵ , M.I. Figueroa ¹ , V. Fink ¹ , M.J. Rolon ² , G. Lopardo ³ , I. Cassetti ⁴ , M.
6	Ceschel ¹ , P. Patterson ¹ , L. Gambardella ¹ , G. Miernes ¹ , A. Nava ¹ , J. Gou ⁵ , R. Wang ⁵ , T.
7	Zhu ⁵ , S.A. Halperin ⁶
8	Authors
9	P. Cahn, PhD (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
10	L. Barreto (5) 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District,
11	Tianjin, PRC
12	M.I. Figueroa, MD. (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
13	V. Fink, MD (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
14	M.J. Rolón, MD. (2) Av. Cerviño 3356, Buenos Aires, C1425AGP, Argentina
15	G. Lopardo, MD. (3) 25 de Mayo 464, Buenos Aires, C1002 ABJ, Argentina
16	I. Casetti, MD (4) Perú 1511, Buenos Aires, C1141ACG, Argentina
17	M. Ceschel, bachelor's degree, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
18	P. Patterson, MD (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
19	L. Gambardella, DMD, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
20	G. Miernes, bachelor's degree, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
21	A. Nava, MD, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.
22	J. Gou (5) 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District,
23	Tianjin, PRC

- 24 R. Wang, PhD (5) 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin,
- 25 PRC
- 26 T. Zhu (5) 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District,
- 27 Tianjin, PRC
- 28 S.A. Halperin (6) 5980 University Ave #5850, Halifax, NS B3K 6R8, Canadá
- 29

30 Institution:

- 31 1 Fundación Huésped, Research Department, Ciudad Autónoma de Buenos Aires, Argentina,
- 32 2 Hospital Juan A. Fernández, Ciudad Autónoma de Buenos Aires, Argentina,
- 33 3 FUNCEI, Ciudad de Buenos Aires, Argentina,
- 34 4 Helios Salud, Ciudad de Buenos Aires, Argentina,
- 35 5 CanSino Biologics Inc, Tianjin, China,
- 36 6 Canadian Center for Vaccinology, Dalhousie University, Halifax, Canada
- 37

38 Corresponding Author

- 39 Pedro Cahn.
- 40 Research Department, Fundación Huésped, Av. Forest 345, Buenos Aires, 1427, Argentina.
- 41 Phone: 54 11 4981 7777
- 42 Email: pedro.cahn@huesped.org.ar

43

45 Summary:

Background: Despite higher risk of poorer outcomes and potential sub-optimal vaccine
effectiveness, people living with HIV (PLWH) are underrepresented in SARS-CoV-2 vaccine
trials. We evaluated the safety and immunogenicity of the Ad5-nCoV vaccine (CanSino Biologics
Inc./The Beijing Institute of Biotechnology) in PLWH.

50

Methods: In this single arm, open-label Phase 2b trial, PLWH were enrolled in Argentina.
Participants received two doses of Ad5-nCoV vaccine (intramuscular, dosage 5x10¹⁰ viral particles) at days 0 and 56. The primary outcomes were safety as serious adverse events [SAE], solicited and unsolicited local and systemic adverse events, impact on HIV viral load and CD4 counts and immunogenicity measured by S-RBD IgG and pseudo-virus neutralizing antibodies (nAbs) up to 52 weeks (ClinicalTrials.gov:NCT05005156).

57

Findings: Between June 2021-January 2022, 140 PLWH received at least one dose of Ad5-nCoV 58 59 vaccine. At baseline, the majority were on antiretroviral therapy (99.3%), virologically suppressed (93.6%), with a median (IQR) CD4-cell count:736 (531-946) cells/ul. At baseline, 38 (27%) 60 participants were seropositive for S-RBD antibodies, and 40 (28%) for nAbs. There were no SAEs 61 related to the vaccine. Solicited AE within 7 days after first and second dose occurred in 93 (69%) 62 and 75 (60%) participants, mostly grade 1, included pain, drowsiness and headache. The incidence 63 64 of unsolicited AE within 28 days of vaccination was 10.7%. There were no significant changes in plasma viral load, CD4, CD4/CD8 ratio and no new AIDS-defining illnesses were reported. There 65 66 were significant increases in the geometric mean titers (GMT) of S-RBD and nAbs between

- baseline to week 52. Seroconversion rates 28 days after the first and second doses (day 84) were
- 68 80% and 94% for S-RBD, and 35% and 78% for nAbs.
- 69
- 70 Interpretation: Two doses of the Ad5-nCoV vaccine were safe and induced an adequate immune
- response in virologically suppressed PLWH, maintaining high antibody titers at least during the
- 72 first year post-vaccination.
- 73
- 74 Funding: CanSino Biologics Inc, Tianjin, China

75	Key words: HIV - VACCINE - SARS-COV - IMMUNE RESPONSE
76	
77	
78	
79	Introduction
80	In March 2020, the World Health Organization declared a global pandemic caused by SARS-CoV-
81	2 (COVID-19). Four years later (March 2024), there have been more than 774 million reported
82	cases and more than 7 million deaths [1]. People living with HIV (PLWH) are at increased risk of
83	worse clinical outcomes after COVID-19 infection, particularly those with lower CD4-cell counts
84	or not receiving antiretroviral therapy (ART)[2,3].
85	Vaccines have played a key role in the public health response to the COVID-19 pandemic. Indeed,
86	shortly after the declaration of the global COVID-19 pandemic, a number of vaccines were rapidly
87	developed and proved to be safe and efficacious in preventing symptomatic COVID-19[4]. In
88	addition, despite lower vaccine effectiveness against variants of concern, their protection against
89	severe COVID-19 has remained high[5].
90	Despite higher risk of poorer outcomes and potential sub-optimal vaccine effectiveness, PLWH
91	have been largely underrepresented in pivotal COVID-19 vaccine trials. PLWHIV represented
92	only 1% (1,557) out of a total number of approximately 150,000 participants enrolled in phase 2/3
93	trials evaluating the mRNA-1273/Moderna, BNT162b2/Pfizer-BioNTech,
94	ChAdOx1/AstraZeneca, NVX-2373/Novavax and Ad26.COV2.S/Janssen vaccines, with other
95	studies completely excluding them[6].
96	To our knowledge, only three trials aimed to address concerns of a potential reduced immune
97	response to COVID-19 vaccines among PLWH: two assessed the ChAdOx1/AstraZeneca

98 vaccine[7,8] and one the NVX-2373/Novavax vaccine[9]. In these studies, two doses of COVID-99 19 vaccines were found to be safe and immunogenic among PLWH, particularly among SARS-100 CoV-2 baseline-seropositive participants. Despite these promising results, sample sizes were small 101 (ranging from 52 to 122), only evaluated two types of vaccines and were conducted in only two 102 countries (UK and South Africa), highlighting the need for additional high-quality experimental 103 studies in PLWH. This is particularly important for SARS-CoV-2 vaccines based on adenovirus 104 type-5 (Ad5) platforms, given prior concerns associated with higher risk of HIV acquisition in 105 participants of Ad5 vectored HIV-1 vaccine trials[10]. Although follow-up data from one of these 106 studies did not find increased risk of HIV progression among participants who became HIV-107 infected[11], it remains critical to monitor the effects of other Ad-5-based vaccines on HIV infection and progression. Therefore, the objective of this study was to assess the safety and 108 109 immunogenicity of two doses of Ad5-nCoV/ CanSino Biologics Inc./The Beijing Institute of 110 Biotechnology in PLWH.

- 111
- 112

Methods

113 Study design

The original protocol (version 1.0) included a 52-week randomized placebo-controlled clinical trial evaluating the safety and immunogenicity of one dose of the Ad5-nCoV vaccine in PLWHIV on stable ART and virologically suppressed. The rapid advancement of the Argentinean COVID vaccination program reduced the possibilities of recruiting the study under such design. Accordingly, the study was amended on October 6th, 2021 to change the study design to a Phase IIB, multicentre, open-label, single-arm trial evaluating the safety and immunogenicity of two doses of the Ad5-nCoV vaccine in PLWHIV (version 1.5). Exclusion criteria based on plasma

HIV viral load or ART status were also removed. The trial was conducted in four sites in Buenos
Aires, Argentina between May 31, 2021, and January 13, 2023, in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines. All participants gave their written informed
consent. The study was approved by ANMAT (Argentina's regulatory agency) and by the
Institutional Review Boards at each participating site, and is registered in clinicaltrials.gov:
NCT05005156.

127

128 Participants

129 We enrolled clinically stable adults (18 years and older) living with HIV who were free from 130 opportunistic infections or AIDS-defining illness for at least six months before screening. Participants were excluded if they had a history of laboratory-confirmed SARS-CoV-2 infection, 131 132 receipt of an adenovirus-vectored, coronavirus, or SARS-CoV-2 vaccine, any AIDS-defining 133 illness, any medical or psychiatric unstable condition (including immunosuppression conditions 134 other than HIV) that in the opinion of the investigator could preclude safe participation in the 135 study, current substance use disorder or history of anaphylaxis to any vaccine component. Women 136 who were pregnant or breastfeeding were not eligible to participate, and all participants involved 137 in heterosexual sexual activity had to agree to the use of approved contraceptive methods.

138

139 **Procedures**

Eligible and consenting participants received two standard 0.5 mL/vial (i.e., 5x10¹⁰vp) intramuscular doses of the Ad5-nCoV vaccine in the deltoid region given eight weeks apart (i.e., day 0 and 56), administered by trained study personnel. The Ad5-nCoV vaccine was produced as previously described[12].

All participants were contacted on a weekly basis (email, telephone, text message) to assess for
any symptoms of COVID-19. The presence of any possible COVID-19 symptoms triggered
laboratory testing for SARS-CoV-2 infection via PCR.

147 Participants were also asked to complete electronic or paper diaries reporting solicited adverse

events (AEs) for 7 days and unsolicited AEs for 28 days after both the first and second vaccination.

- 149 Serious adverse events (SAE) and medically attended adverse events (MAAE) were collected
- throughout the 52-week duration of the trial and recorded every 4 weeks via telephone calls.

A baseline SARS-CoV-19 antibody, and a urine pregnancy test in women of child-bearing potential was performed on Day 0, immediately before vaccination. Blood samples for immunogenicity analysis were collected on days 0, 28, 84, and weeks 24 and 52. Immunogenicity measures included IgG antibodies to the receptor-binding domain of the SARS-CoV-2 spike protein 9 (S-RBD IgG antibody), measured by ELISA-based assays and neutralising antibodies against SARS-CoV-2 (nAbs), measured by pseudovirus neutralisation assays. HIV viral load, CD4 and CD8-cell counts were measured on day 0, and weeks 24 and 52.

158

159 Outcomes

The two co-primary outcomes were the safety and immunogenicity profile of the Ad5-nCoV vaccine. Safety was assessed by the incidence of solicited and unsolicited AE occurring within 7 and 28 days of each vaccination, respectively, SAE and MAAE throughout the study period, as well as HIV viral load at weeks 24 and 52. Immunogenicity was evaluated by the seroconversion rate of the S-RBD IgG antibody on Day 28, Day 84, Week 24, and Week 52 after vaccination. Secondary safety outcomes included the incidence of a decrease in CD4-cell count by >=20% as well as the change of the CD4/CD8 ratio from the baseline value. Secondary immunogenicity

outcomes included the seroconversion rate of nAbs, as well as the geometric mean titer (GMT)
and geometric mean increase (GMI) of the S-RBD IgG antibody and nAbs at Day 28, Day 84, and
Week 24 and Week 52 after vaccination.

Exploratory outcomes included the efficacy of two doses of Ad5-nCoV in preventing PCRconfirmed symptomatic COVID-19 occurring 14 and 28 days after the second dose (i.e., days 70 and 84) up to last study visit.

173

174 Statistical analysis

175 Given that this was a non-comparative study; no formal sample size calculation was performed. 176 The safety analysis population included all participants who received at least one dose of the Ad5nCoV vaccine. Separate safety analyses were conducted for the first and second doses. Safety 177 178 endpoints were summarized using frequency counts and percentages. The immunogenicity 179 analysis population included participants with at least one dose of the vaccine and available antibody results. GMT, GMI, and seroconversion rate (with corresponding 95% confidence 180 181 intervals) were calculated for each time point, using mixed effects linear regression models to 182 assess changes over time. The seroconversion rate was calculated as the proportion of participants that had a GMI of the S-RBD IgG antibody or nAbs equal to or greater than 4 from baseline at 183 184 each pre-specified time point. At baseline, participants with S-RBD IgG antibody or nAbs titers greater than 4 were considered positive. The evaluation of changes in the proportion of participants 185 186 with undetectable VL, log10 VL, CD4/CD8-cell counts and CD4/CD8 ratio was performed fitting a mixed effects linear regression model, setting as fixed independent variable the time as a 187 188 continuous variable, and subject as random term.

- 189 The analysis of the exploratory efficacy endpoint was descriptive and performed in the total
- 190 participants that were vaccinated with two doses.
- 191 All statistical analysis was performed using R Statistical Software[13].
- 192
- 193

Results

194 Baseline characteristics

195 Between May 31, 2021 and January 6, 2022, 141 PLWHIV were enrolled in this study. Of these, 196 140 participants received at least one dose of the Ad5-nCoV vaccine (one participant withdrew 197 consent before receiving any dose) and were included in this analysis: 133 participants received 198 two doses and 7 participants one dose. Figure 1 shows the CONSORT flow diagram of participants and Table 1 summarizes the participants' baseline sociodemographic and clinical characteristics. 199 200 The median age was 41 (Interquartile range [IQR]: 31-48), 79.0% were males and 97.9% self-201 reported white race. All except one participant (n=139, 99.3%) were on ART, the majority (93.6%) 202 were virologically suppressed (VL <40 copies/mL) and the median (IQR) CD4-cell count was 736 203 (531-946) cells/ul. At baseline, 38 (27%) participants were seropositive for S-RBD antibodies, and 204 39 (28%) were seropositive for nAbs.

205

206 Table 1. Baseline characteristics of the study population (N=140)

Male	79% (70.7-84.9) [110]
Female	21% (15.1-29.3) [30]
Race - % (95%CI) [n]	
White	97.9% (93.4-99.4) [137]
American Indian or Alaska Native	0.7% (0.4-4.5) [1]
Black	0.7% (0.4-4.5) [1]
Other	0.7% (0.4-4.5) [1]
on Antiretroviral therapy - % (95%CI) [n]	99.3% (97.9-100) [139]
Virologically suppressed /≤ 40	93.6% (87.8-96.8) [131]
copies per mL-	
% (95%CI) [n]	
CD4 count (cells/ul) - median (IQR*)	735.5 (530.5-945.8)

208

*median (percentiles 25-75).

209

210 Safety analysis

Solicited AE diaries were completed by 135 participants (96%) after the first dose, and 125
participants (94%) after the second dose. The proportion of participants reporting solicited
systemic and local AE after the first and second dose are presented in Figure 2. After the first dose,
93 participants (69%) reported at least one solicited AE, mostly grade 1. Pain (48%) was the most

common local solicited AE and drowsiness (39%) and headache (34%) the most common systemic

solicited AE. After the second dose, 75 participants (60%) reported at least one solicited AE. A

similar pattern of solicited AE was observed after the first and second dose though the proportion

218 of participants reporting systemic solicited AE was lower (25% drowsiness, 23% headache).

The global incidence of unsolicited AE within 28 days of vaccination was 10.7% (15 events: 11

events after the first dose and 4 events after the second dose). The most frequent one was asthenia

221 (7 events), only one was grade 3, and none required hospitalization.

Over the 52-week duration of the study, there were 8 SAEs (none of them related to the studyvaccine). Two participants died, one due to myocardial infarction complicated with severe bilateral

224 COVID pneumonia and the other due to fatal respiratory failure secondary to lung cancer.

A total of 141 MAAEs in 70 participants (50%) were reported, including 18 COVID-19 confirmed
cases and 33 suspected cases. Most of the MAAEs were grade 2 (74%). Two MAAEs were

227 possibly related to the study drug: acute unilateral hearing loss and fever of unknown origin.

HIV VL and CD4/CD8 cell count measurements at baseline, week 24 and 52 after the first vaccine dose are presented in Table 2. There were no significant changes in the proportion of participants who were virologically suppressed or the log10 VL in non-suppressed participants between baseline and the other time points. The mixed effects linear regression model fit showed a statistically significant increase of CD4, CD8-cell count mean, as well as CD4/CD8 ratio mean over time (p < 0.001)[14].

A decrease of CD4-cell count of 20% or higher from baseline was observed in 22.6% of

participants at week 24, and 12.2% at week 52. None of these participants had less than 200 CD4

cells per mL at any point in time, and there were no AIDS-defining illnesses during the

237 observation period.

238 Table 2. HIV viral load, CD4 and CD8 cell count measurements at baseline, week 24 and

239 week 52 after the first Ad5-CoV vaccine dose

240

	Baseline	Week 24	Week 52	p-value
	(n=140)	(n=124)	(n=123)	
Virologically	131 (94)	113 (91)	112 (91)	0.199
suppressed (<=				
40 copies/ mL),				
n (%)				
log10 HIV-VL	3.38 (2.37-4.59)	2.38 (1.74-3.78)	1.97 (1.77-3.46)	0.062
in non-				
suppressed				
participants,				
median (IQR)				
CD4-cell count,	735	703.5	789	<0.001
median (IQR)	(530.5-945.8)	(515.8-940.5)	(620-996.5)	
CD8-cell count,	886 (699-1144)	833 (635.25-	1045	<0.001
median (IQR)		1059.5)	(751-1328)	
CD4/CD8 ratio	0.80	0.85	0.82	<0.001
	(0.57-1.16)	(0.60-1.14)	(0.55-1.10)	

242 Immunogenicity analysis

Immunogenicity analysis included samples from the 140 participants who received at least one
vaccine dose and had available S-RBD antibodies and n-Abs results, excluding samples taken after
COVID-19 confirmed cases: 139 samples for day 0, 135 for day 28, 127 for day 84, 104 for week
24, and 73 for week 52. Sixty-four samples were excluded due to SARS-CoV-2 confirmed

247 infection. Tables 3 and 4 present GMT, GMI, and seroconversion rates at pre-specified time points

248 for S-RBD antibodies and nAbs, respectively.

At baseline, the GMT of S-RBD antibodies was 7.02 (95% Confidence Interval 5.79-8.51), with

250 38 (27%) participants being categorized as seropositive for S-RBD antibodies. The Ad5-CoV

251 vaccine elicited a strong anti-S-RBD antibody response, which increased after the second dose.

252 There were statistically significant increases in the S-RBD GMT between baseline and all the other

visits. Seroconversion of the anti-RBD antibodies occurred in 108/135 (80%) participants on day

254 28, 118/127 (93%) on day 84, 87/104 (84%) on week 24, and 61/73 (84%) on week 52. Five
255 subjects never reached S-RBD seroconversion.

At baseline, the GMT of nAbs was 5.54 [95% CI 4.88 – 6.30], with 40 (28.1%) participants being
categorized as sero-positive for nAbs. nAbs seroconversion occurred in 47/135 (35%) participants
at day 28, 99/127 (78%) at day 84; 59/104 (57%) at week 24 and 57/73 (78%) at week 52. There
were 21 subjects who did not reach seroconversion of nAbs titers at any time point.

Post-hoc analyses indicated that although there was a significant increase in the GMT of S-RBD antibodies and nAbs in both SARS-Cov-2 sero-positive and sero-negative participants, GMT were significantly higher in sero-positive participants at all time points. Of note, it appears that the GMI rate after the second dose was higher in the SARS-Cov-2 sero-negative group(supplementary figure).

265

Table 3. S-RBD antibodies at pre-specified time points after vaccination* p < 0.05

	Day 0	Day 28	Day 84	Day 168	Day 364	p-value
	n=139	n=135	n=127	n=104	n=73	
GMCs of S-	7.02	103.04	260.21	7.46 (123.53	395.29	<0.01*
BD	.79 - 8.51)	(75.90 -	(209.08 -	- 254.93)	(257.56 -	
antibodies.		139.88)	323.84)		606.66)	
GMC (CI						
%)						
**GMI of S-		14.56	35.57	22.92	46.20	
BD a		1.36-18.65)	8.16-44.94)	5.68-33.50)	8.34-74.33)	
tibodies.						
GMI (CI 95%)						
		108 (80)	118 (93)	87 (84)	61 (84)	
roconversion, n						
)						

** GMCs and CI 95% are presented. Comparison between visits were performed by Friedman test
for paired data on a logarithmic scale. Post-hoc analysis (pairwise comparisons) was performed by
Wilcoxon signed rank test with continuity correction, and Bonferroni's method for multiple
comparison correction was applied.

- ***GMI (the geometric mean increase) was calculated as the geometric mean of the ratios of the
- titer of the visit to the baseline titer.
- 274
- 275
- 276

277 Table 4. SARS-CoV-2 neutralizing antibodies at pre-specified time points after vaccination

	Day 0	Day 28	Day 84	Day 168	Day 364	p-value
	n=139	n=135	n=127	n=104	n=73	
**						<0.01*
GMTs of	5.54	15.73	46.10	36.17	73.94	
SARS-CoV-	(4.88-	(11.71-	(35.88-	(25.35-	(50.16-	
2	6.30)	21.14)	59.24)	51.62)	108.99)	
neutralizing						
antibodies.						
GMT (CI						
95%)						
**						
GMI of		2.83	8.15	6.12	11.64	
SARS-CoV-		(2.26-	(6.64-	(4.43-	(7.94-	
2		3.54)	9.98)	8.45)	17.08)	

neutralizing					
antibodies.					
GMI (CI					
95%)					
Seroconversion	47 (35)	99 (78)	59 (57)	57 (78)	
, n (%)					

278

279

280 Exploratory efficacy analysis

There were 45 PCR-confirmed COVID cases among the 133 participants who received two vaccine doses. Of these, 42 (31.6%) occurred within14 days after the second dose: 1 case between 14 and 28 days after the second dose, and 41, between 28 days and 52 weeks. None of the COVID confirmed cases met severe disease criteria. The median time between the application of the second dose and the start date of COVID-19 was 135 days (IQR:81-193). Over half of the COVIDconfirmed cases (25/42) occurred in January 2022, when Argentina was in the midst of a new wave of Covid-19 associated with the emergence of the Omicron variant.

289

Discussion

290 Meta-analyses evaluating the immunogenicity and safety of COVID-19 vaccines in PLWH have 291 shown a favorable, though not optimal immune response to COVID-19 vaccines in PLWH[15].

292 While most studies have shown comparable seroconversion rates to the general population, results 293 on the magnitude of the antibody response have been less consistent with some studies reporting 294 no differences, and other showing lower antibody titers in PLWH. These disparities may be due to 295 the high heterogeneity among studies, including study population, vaccine type, time between 296 vaccine dose and serology testing and definition of seroconversion. Our study adds to the literature 297 by evaluating for the first time an Ad5-nCoV vaccine in PLWH. We found that two doses of the 298 Ad5-nCoV vaccine were well-tolerated and produced an adequate and sustained immune response 299 in PLWH well controlled on ART in Argentina. In addition, the Ad5-nCoV vaccine had a neutral 300 effect on HIV surrogate markers.

In this study, vaccination with Ad5-nCoV had a favourable safety profile with no vaccine-related
SAEs, and most solicited AEs being mild in severity. These findings are similar to the previously
reported safety profile in the general adult population enrolled in the phase 3 Ad5-nCoV trial[12].
No significant changes in HIV surrogate markers as HIV plasma viral load were found, and CD4,
CD8, and CD4/CD8 ratios remained stable across the observation period.

306 Consistent with prior meta-analysis [15,16], our results indicate a favorable immune response to 307 the Ad5-nCoV vaccine in PLWH. For S-RBD antibodies, there was a GMI of almost 15 fold after 308 the first dose, increasing to 35 fold after the second dose, with sustained GMT S-RBD antibodies 309 for up to a year and seroconversion rates of more than 80% of participants. Development of a 310 neutralising antibody response was lower, with a GMI of 2.8 and 8 fold after the first and second 311 dose. The seroconversion rate after the first dose was only 35%, but increased to more than 75% 312 after the second dose. The immune response to the Ad5-nCoV vaccine in PLWH in this study 313 however, appeared to be lower than that observed after one dose of the Ad5-nCoV in the general 314 adult population, particularly for nAbs. Altogether, these findings suggest that two doses of Ad5-

nCoV may be needed in PLWH to achieve adequate protection, given evidence indicating a strong
correlation between nAbs and vaccine efficacy against COVID-19[17].

317 This study has some limitations. First, this was an open-label single arm study, without concurrent 318 recruitment of adults without HIV, and thus post-hoc comparisons with the general population 319 from the phase 3 Ad5-nCoV trial should be interpreted with caution. Second, we included PLWH 320 who were mostly on ART, with well controlled HIV infection and good immunological status. 321 Additionally, our study population predominantly consisted of white men. This may limit the 322 generalizability of our findings to the overall population of PLWH, without previously considering 323 their immunosuppression and ART status, sex or race. Third, although seroconversion rate is a 324 proxy for vaccine efficacy, our study was not powered to evaluate clinical efficacy endpoints and the estimated sample size changed after he rapid advancement of the Argentinean COVID 325 326 vaccination program. Also a limitation is the number of samples available for immunogenic 327 analyzes through the 52 weeks.

In conclusion, two doses of the Ad5-nCoV vaccine were safe and induced an adequate immune response in virologically suppressed PLWH, maintaining high antibody titers at least during the first year post-vaccination. Future studies should evaluate the clinical efficacy of various immunization strategies with the Ad5-nCoV vaccine in a diverse population of PLWH (including those with more advanced immunosuppression) in preventing breakthrough infections and severe COVID-19 disease by emerging variants of concern.

334

335 Contributors

PC, LB, TZ, SH designed the study, and wrote the study protocol. MC,- GM, AN oversaw
statistical analyses. PC, MIF, GL, IC, MJR, and MY accessed and verified the underlying data in

338	the manuscript. LG and the quality team led the implementation and study quality assurance. All
339	authors had full access to all the data in the study and had final responsibility for the decision to
340	submit for publication. All authors approved the final manuscript.
341	
342	Declaration of interests
343	PC received grant support to his institution from CanSino Biologics Inc. To carry out this study as
344	an investigator initiative, Fundacion Huesped was responsible for site selection, study
345	implementation, quality control and assurance, and general overview of the study. Other authors
346	declare no competing interests.
347	
348	Data sharing
349	Fundacion Huesped and the Canadian Center for Vaccinology shared anonymised individual
350	patient data with Cansino Biologistic Inc.
351	
352	Role of the funding source
353	CanSino Biologics provided the vaccine and placebo, as well as the funds for the study.
354	
355	Acknowledgements
356	We want to acknowledge the invaluable and generous contributions of all study participants and
357	their families, and of all the staff across the participant sites who supported recruitment and
358	retention into the study. We acknowledge M. Eugenia Socias for her contribution to the writing of
359	this manuscript, Javier Mariani and team for the statistical analysis, and Meixu Yan for the

360 contribution, support and work on the manuscript.

362		
363		
364		
365		
366		
367		
368		
369		
370	Ref	erences
371	1.	COVID-19 Cases WHO COVID-19 Dashboard Available online:
372		https://data.who.int/dashboards/covid19/cases (accessed on 5 July 2024).
373	2.	Ambrosioni, J.; Blanco, J.L.; Reyes-Urueña, J.M.; Davies, MA.; Sued, O.; Marcos, M.A.;
374		Martínez, E.; Bertagnolio, S.; Alcamí, J.; Miro, J.M.; et al. Overview of SARS-CoV-2
375		Infection in Adults Living with HIV. Lancet HIV 2021, 8, e294–e305, doi:10.1016/S2352-
376		3018(21)00070-9.
377	3.	Danwang, C.; Noubiap, J.J.; Robert, A.; Yombi, J.C. Outcomes of Patients with HIV and
378		COVID-19 Co-Infection: A Systematic Review and Meta-Analysis. AIDS Res. Ther. 2022,
379		19, 3, doi:10.1186/s12981-021-00427-y.
380	4.	Graña, C.; Ghosn, L.; Evrenoglou, T.; Jarde, A.; Minozzi, S.; Bergman, H.; Buckley, B.S.;
381		Probyn, K.; Villanueva, G.; Henschke, N.; et al. Efficacy and Safety of COVID-19
382		Vaccines. Cochrane Database Syst. Rev. 2022, 12, CD015477,
383		doi:10.1002/14651858.CD015477.

- 384 5. Zeng, B.; Gao, L.; Zhou, Q.; Yu, K.; Sun, F. Effectiveness of COVID-19 Vaccines against
- 385 SARS-CoV-2 Variants of Concern: A Systematic Review and Meta-Analysis. *BMC Med.*
- **2022**, *20*, 200, doi:10.1186/s12916-022-02397-y.
- 387 6. Höft, M.A.; Burgers, W.A.; Riou, C. The Immune Response to SARS-CoV-2 in People

388 with HIV. Cell. Mol. Immunol. 2024, 21, 184–196, doi:10.1038/s41423-023-01087-w.

- 389 7. Frater, J.; Ewer, K.J.; Ogbe, A.; Pace, M.; Adele, S.; Adland, E.; Alagaratnam, J.; Aley,
- 390 P.K.; Ali, M.; Ansari, M.A.; et al. Safety and Immunogenicity of the ChAdOx1 NCoV-19
- 391 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: A Single-Arm Substudy of a
- 392 Phase 2/3 Clinical Trial. *Lancet HIV* **2021**, *8*, e474–e485, doi:10.1016/S2352-
- **393 3018**(21)00103-X.
- 8. Madhi, S.A.; Koen, A.L.; Izu, A.; Fairlie, L.; Cutland, C.L.; Baillie, V.; Padayachee, S.D.;
- 395 Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and Immunogenicity of the ChAdOx1
- 396 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without
- 397 HIV in South Africa: An Interim Analysis of a Randomised, Double-Blind, Placebo-
- 398 Controlled, Phase 1B/2A Trial. *Lancet HIV* **2021**, *8*, e568–e580, doi:10.1016/S2352-
- 399 3018(21)00157-0.
- 400 9. Madhi, S.A.; Moodley, D.; Hanley, S.; Archary, M.; Hoosain, Z.; Lalloo, U.; Louw, C.;
- 401 Fairlie, L.; Fouche, L.F.; Masilela, M.S.L.; et al. Immunogenicity and Safety of a SARS-
- 402 CoV-2 Recombinant Spike Protein Nanoparticle Vaccine in People Living with and without
- 403 HIV-1 Infection: A Randomised, Controlled, Phase 2A/2B Trial. *Lancet HIV* 2022, 9,
- 404 e309–e322, doi:10.1016/S2352-3018(22)00041-8.
- 405 10. Buchbinder, S.P.; McElrath, M.J.; Dieffenbach, C.; Corey, L. Use of Adenovirus Type-5
- 406 Vectored Vaccines: A Cautionary Tale. *The Lancet* **2020**, *396*, e68–e69,

407 doi:10.1016/S0140-6736(20)32156-5.

- 408 11. Fitzgerald, D.W.; Janes, H.; Robertson, M.; Coombs, R.; Frank, I.; Gilbert, P.; Loufty, M.;
- 409 Mehrotra, D.; Duerr, A.; Step Study Protocol Team An Ad5-Vectored HIV-1 Vaccine
- 410 Elicits Cell-Mediated Immunity but Does Not Affect Disease Progression in HIV-1-
- 411 Infected Male Subjects: Results from a Randomized Placebo-Controlled Trial (the Step
- 412 Study). J. Infect. Dis. 2011, 203, 765–772, doi:10.1093/infdis/jiq114.
- 413 12. Halperin, S.A.; Ye, L.; MacKinnon-Cameron, D.; Smith, B.; Cahn, P.E.; Ruiz-Palacios,
- 414 G.M.; Ikram, A.; Lanas, F.; Guerrero, M.L.; Navarro, S.R.M.; et al. Final Efficacy
- 415 Analysis, Interim Safety Analysis, and Immunogenicity of a Single Dose of Recombinant
- 416 Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years and Older: An
- 417 International, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Phase 3 Trial.

418 *The Lancet* **2022**, *399*, 237–248, doi:10.1016/S0140-6736(21)02753-7.

- 419 13. R Foundation for Statistical Computing R: A Language and Environment for Statistical
- 420 Computing. Available online: https://www.r-project.org/ (accessed on 22 April 2024).
- 421 14. Vergori, A.; Cozzi-Lepri, A.; Tavelli, A.; Mazzotta, V.; Azzini, A.M.; Gagliardini, R.;
- 422 Mastrorosa, I.; Latini, A.; Pellicanò, G.; Taramasso, L.; et al. SARS-CoV-2 MRNA
- 423 Vaccination and Short-Term Changes in Viral Load and CD4/CD8 T Cell Counts in People
- 424 Living with HIV. Int. J. Infect. Dis. 2024, 0, doi:10.1016/j.ijid.2024.107065.
- 425 15. Søndergaard, M.H.; Thavarajah, J.J.; Churchill Henson, H.; Wejse, C.M. SARS-CoV-2
- 426 Vaccine Immunogenicity for People Living with HIV: A Systematic Review and Meta-
- 427 Analysis. *HIV Med.* **2024**, *25*, 16–37, doi:10.1111/hiv.13537.
- 428 16. Kang, L.; Shang, W.; Gao, P.; Wang, Y.; Liu, J.; Liu, M. Immunogenicity and Safety of
- 429 COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-

- 430 Analysis. *Vaccines* **2022**, *10*, 1569, doi:10.3390/vaccines10091569.
- 431 17. Khoury, D.S.; Schlub, T.E.; Cromer, D.; Steain, M.; Fong, Y.; Gilbert, P.B.; Subbarao, K.;
- 432 Triccas, J.A.; Kent, S.J.; Davenport, M.P. Correlates of Protection, Thresholds of
- 433 Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. *Emerg.*
- 434 Infect. Dis. 2023, 29, 381–388, doi:10.3201/eid2902.221422.
- 435

Figure 1. Consort Study Flow Chart



Figure 2. Proportion of participants reporting solicited systemic (A) and local (B) adverse events in participants vaccinated with at least one dose of the Ad5-CoV vaccine, after first (left) and second (right) dose.

The figure summarizes AEs at any day & grade up to 7 days after vaccination. Solicited AE diaries were completed by 135 participants after the first dose and 125 participants after the second dose.

